Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF | Spanish ecancer 12 835 / https://doi.org/10.3332/ecancer.2018.835

Research

Phase I/II study on kilovoltage surface brachytherapy in conjunctival cancer: preliminary results

Introduction: In ocular conjunctival carcinoma after surgery, adjuvant treatment has a role and kilovoltage surface brachytherapy opens a new door for the range of therapeutic options.

Materials and methods: Between October 2014 and June 2017, at the National Institute of Neoplastic Diseases (INEN) from Peru, 39 patients with squamous cell carcinoma of ocular conjunctiva, T1–T3, resected, were selected to receive adjuvant treatment. The portable accelerator of 50-kV INTRABEAM (Carl Zeiss Meditec) was used, after local anaesthesia and blocking of ocular muscles movement. The doses used were 18 Gy for patients with free margins and 22 Gy for positive edges, according to calculation of equivalent dose of 2Gy per fraction of 46 and 66 Gy, respectively, assuming a tumoural α/β ratio of 8 Gy. The prescription was done to 2 mm depth.

Results: The median age was 69 years, distributed evenly between both genders, with a median follow-up of 12 months. The surgical margins were 59% free and 41% committed, with no difference between the institutions where the surgery was performed (P = 0.069). The median tumour size was 7 mm with 2 mm of invasion, 61.5% was T2 and 35.9% T1. The mean time between surgery and irradiation was 1.5 months, 23.1% of patients developed grade I toxicity of spontaneous resolution, without evidence of greater degree in any case. The dose had no statistical relationship with toxicity (P = 0.533). One-year disease-free survival was 96.7%.

Conclusions: Kilovoltage surface brachytherapy is an applicable and reproducible tool in the treatment of squamous cell carcinoma of ocular conjunctiva. The administered doses are well tolerated by patients with low levels of acute toxicity. Longer follow-up is needed to establish disease control rates and late toxicities.

Keywords: surface brachytherapy, kilovoltage, conjunctival carcinoma

Loading Article Metrics ... Please wait

Related articles

Conference Report: From science to real-life oncology—the ECCO 2018 European Cancer Summit, 7–9 September 2018, Vienna, Austria

Abstract | Full Article | PDF Published: 15 Oct 2018 / https://doi.org/10.3332/ecancer.2018.877

Research: Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study

Abstract | Full Article | PDF Published: 09 Oct 2018 / https://doi.org/10.3332/ecancer.2018.876

Short Communication: Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series

Abstract | Full Article | PDF Published: 02 Oct 2018 / https://doi.org/10.3332/ecancer.2018.875

Review: Clinical decision making in postmastectomy radiotherapy in node negative breast cancer

Abstract | Full Article | PDF Published: 26 Sep 2018 / https://doi.org/10.3332/ecancer.2018.874

Research: What information do cancer patients want and how well are their needs being met?

Abstract | Full Article | PDF Published: 25 Sep 2018 / https://doi.org/10.3332/ecancer.2018.873



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation